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ABSTRACT 
Objective: The objective of this research was to show quercetin potency to inhibit histone acetyltransferase p300/CBP-associated factor (HAT 
PCAF) activity. Molecular docking study was used to show inhibition model of quercetin towards HAT PCAF and the kinetic study was used to give 
the information about inhibition constant (Ki) of quercetin. 
Methods: Molecular docking simulations between HAT and quercetin were performed using AutoDock Vina, and the results were scored based on 
its Gibbs free energy change (ΔG) (the most negative ΔG). The kinetic assay of HAT PCAF inhibition by quercetin used fluorometry methods to 
measure enzyme inhibition by quercetin.  
Results: Molecular docking showed that quercetin could inhibit HAT PCAF through binding to acetyl-CoA that involved glutamine 525 (Gln525) and 
cysteine 574 (Cys574) on chain A, and Cys574 and Gln581 on chain B of HAT PCAF. Quercetin also binds to histone active site on HAT PCAF through 
aspartic acid 610 (Asp610). The kinetic study results showed that quercetin could inhibit histone acetylation based on the fluorescence intensity. 
Analysis by Dixon plot showed that quercetin competes with histone. Therefore, it had competitive inhibition. Its Ki value of 9.575 µM. Kinetic study 
showed the same result as molecular docking study that quercetin had potency as an HAT PCAF inhibitor. 
Conclusion: The result of this research showed that quercetin had the potency to inhibit HAT PCAF through competition with HAT PCAF substrates. 
Quercetin could interact with the HAT PCAF active site, thus, lower the HAT PCAF activity.  
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INTRODUCTION 
Histone acetylation is one of the epigenetic modifications, and the 
effects are very important for development, differentiation, and 
cellular processes of an organism [8]. Histone acetylation catalysis by 
HAT through transfer acetyl group from acetyl-CoA to lysine ε-amino 
group on histone causes chromatin structure into a relaxation form 
that leads to recruitment of transcription factors, resulting in 
activation of DNA transcription. This activation affects the level of gene 
expression, mitosis, meiosis, cell differentiation, and DNA replication 
[1, 2, 7, 14]. Errors that occur during these modifications are 
particularly vulnerable as one of the causes of cancer, inflammation, 
and viral infections [7].  
HAT has different types, but p300/CBP and PCAF are the HATs are 
found in human [2, 17]. HAT’s substrates could be histone or 
nonhistone proteins, such as p53 and nuclear factor-kappa beta (NF- κ) 
[21]. Hyperacetylation on histone can cause an increase in cell 
proliferation, and acetylation on p53 can inactivate tumor suppressor 
thus p53 cannot repair DNA or inhibit apoptosis [20]. Those are some 
factors that are associated with cancer manifestation. HAT as 
transcription cofactor has an important role in transcription regulation 
through transcription factors binding. Interference in this enzyme can 
lead to several diseases, such as cancer and neurodegenerative. 
Therefore, HAT PCAF can be used as an anticancer target. 
Epigenetic drugs development is very rapid and is intended as an 
alternative cancer therapy. Epigenetic drugs that have been accepted 
by the Food and Drug Administration (FDA) are Dacogen and Vizada to 
inhibit DNA methylation, and Vorinostat and Romidepsin as a histone 
deacetylase (HDAC) inhibitor [3], whereas histone acetyltransferase 
inhibitor, is still in the pre-clinical stage [16]. HAT inhibitors are in the 
development stage either natural or synthetic products, such as 
curcumin, garcinol, isothiazolone, anacardic acid, C646, H3-CoA-20, 
and Lys-20. The problem with the development of these inhibitors is 
the permeability of the cell or low specificity [2, 7, 11, 13]. Therefore, 
the development of small inhibitors with a cell permeability and high 
specificity against HAT PCAF needs further study.  
Natural products from plants that showed potential as HAT inhibitors 
are quercetin, a common flavonoid found in plants. Quercetin has 
antioxidant effects, furthermore, it can inhibit macrophage 
proliferation, and nuclear factor κB (NF-κB) [5]. Quercetin inhibits 
transcription factor, NF-κB, recruitment at the chromatin of 
proinflammatory genes [23]. Quercetin also has potential to inhibit 
HAT p300 in breast cancer [25]. 
Studies about quercetin as HAT p300 inhibitor have been done [23], 
whereas a study about quercetin potential as an inhibitor against HAT 
PCAF has not been done. In addition, inhibition kinetics of quercetin 
against HAT PCAF is still unknown. This study predicts an interaction 
model between quercetin and HAT PCAF in silico by using molecular 
docking technique. HAT inhibition kinetic assay by quercetin (in vitro) 
was carried out after the molecular docking in silico. This kinetic 
inhibition assay provides information about the inhibition type and the 
inhibition constant value which is also a parameter to be considered 
for determining quercetin potential in inhibiting HAT PCAF activity. 
MATERIALS AND METHODS  
Materials 
All the reagents were from Sigma-Aldrich, except HAT buffer pH 7.5 
(Cayman Chemical Company) unless stated otherwise. 
Materials used in the molecular docking were two-dimension of 
quercetin structure and three-dimension of HAT PCAF structure (code: 
1CM0) obtained from http://www.rscb.org/pdb. Kinetic inhibition 
assay used HAT PCAF human recombinant, purity ˃95% by SDS-PAGE 
were expressed in Escherichia coli, quercetin with purification 95% by 
HPLC, histone-3 (H3) peptide purification 90%, acetyl-CoA with 
purification 93% by HPLC, Coenzyme A, and CPM as probe, all the 
materials obtained from Sigma-Aldrich, while buffers HAT (5x) used 
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consists of HEPES buffer, and Triton-X, and ultrapure water obtained 
from Cayman. This assay also used dimethyl sulfoxide (DMSO) as a 
solvent and isopropanol to stop the reaction.  
Molecular docking simulation of HAT and quercetin 
Molecular docking simulation used was molecular docking methods 
adapted from previous studies [24]. The crystal structure of PCAF was 
downloaded from Protein Data Bank (code 1CM0). Quercetin was 
drawn using Chemaxon Marvin Sketch and prepared using Open Babel 
GUI (to convert pdb format to pdbqt). Quercetin availability was 
analyzed by Lipinski rule. Molecular docking simulations were 
performed using AutoDock Vina. Molecular docking results were 
scored based on its ΔG to obtain the best value (the most negative ΔG). 
Molecular interaction such as hydrogen bond, hydrophobic interaction, 
and the bond was at a distance from the result of AutoVina docking 
visualized by using Ligplot+1.5.4. 
HAT inhibition kinetic assay  
HAT inhibition kinetic assay procedures were adapted from previously 
described methods [13]. All of the reagents were from Sigma-Aldrich 
unless stated otherwise. The final concentrations of each reagents 
were 10 and 15 μM histone 3 peptide, 2 μM acetyl-CoA, 0, 10, 20, 30, 
40, 50 μM quercetin, and 5 nM PCAF. The HAT inhibition assay was 
carried out at 30 °C for 10 min in 1x HAT buffer pH 7.5 (Cayman 
Chemical Company) that consisted of HEPES (free acid), triton X-100, 
and water. The reaction was stopped with 10 μl isopropanol. Hereafter, 
50 μM CPM as the probe was added to the reaction, followed by 
incubation for the next 10 min. Total volume for this reaction was 100 
μl. Relative fluorescence unit (RFU) was measured by Fluostar Omega 
with 392 nm and 482 nm for excitation and emission wavelength, 
respectively. This assay was carried out in duplo. 
Inhibition kinetic analysis  
The histone final concentrations and reaction rate were measured 
from its relative fluorescence units (RFU). The high RFU indicated high 
HAT activity and vice versa. The measurable RFU plotted to a linear 
equation of the standard curve. Dixon plot was used to for HAT 
inhibition analysis. The histone final concentrations and reaction rate 
were plotted to Dixon plot to obtain the inhibition constant value and 
the inhibition type of quercetin against HAT. 
RESULTS AND DISCUSSION 
Quercetin characteristics 
Chemical substances that will serve as drug candidates need to fulfill 
some physicochemical properties including absorption, distribution, 
metabolism, excretion, and toxicity [26]. Absorption is the initial 
parameters that need to be considered in drug development; it is 
associated with the bioavailability. The first screening of drug 
candidates related to its absorption characteristic can be done with in 
silico methods if it fulfilled Lipinski rule. Chemical components of drug 
candidates are membrane permeable and easily absorbed by the body 
if it meets the following criteria: (1) molecular mass less than 500 
g/mol; (2) chemical component lipophilicity expressed as logarithm of 
the partition coefficient between water and 1-octanol (logP) less than 
5; (3) less than 5 hydrogen bond donors; (4) less than 10 hydrogen 
bond acceptors [15]. The analysis of quercetin characteristics result 
indicates that quercetin has quite a good bioavailability because it 
meets all the parameters of Lipinski rules (table 1). 
Lipophilicity is an important parameter in drug development. 
Lipophilicity has an impact on all part of the pharmacokinetic profile of 
oral drugs, such as solubility, absorption, the permeability of the cell, 
binding to plasma proteins, metabolism, and final excretion [9]. 
Lipophilicity optimum range, along with low molecular mass and 
narrow polar surface area greatly affects the level of chemical 
substances absorption in the intestine by passive diffusion. 
Lipophilicity plays an important role in regulating kinetics and 
dynamics aspects of drugs [17]. Drug’s lipophilicity expressed in log P 
between 1-octanol and water (1-octanol/water). The partition 
coefficient is the concentration ratio of a component in a mixture of 
immiscible phases under an equilibrium condition. Quercetin 
coefficient partition value of 0.269279 (<5) meet the Lipinski rule. This 
value indicates that quercetin is easily absorbed by the body.  
Molecular mass also affects the absorption rate of drugs in the body. 
The higher molecular mass associated with poor permeability through 
the intestine [15]. Quercetin molecular mass of 316 g/mol showed that 
quercetin eligible Lipinski rule, which is less than 500 g/mol so that 
quercetin is considered quite easy to be absorbed by the body. 
Another Lipinski parameter is the number of proton donors and 
acceptors. The excessive number of hydrogen bond donors and 
acceptors that excess can interfere with drug permeability across the 
membrane bilayer [15]. The number of hydrogen bond donors and 
acceptors of quercetin respectively by 5 and 6 showed that quercetin 
also meet the parameter of Lipinski, therefore quercetin can be used to 
stimulate interaction with histone acetyltransferase. Quercetin meets 
all the Lipinski rules, consequently, it can be used as ligands in the 
fixation with the enzyme target.  
 
Table 1: Quercetin characteristics 
Characteristics Quercetin 
Molecular mass (<500 g/mol) 316 Da 
Octanol-water partition coefficient (logP<5) 0.269279 
Hydrogen bond receptor (<5) 5 
Hydrogen bond acceptor (<10) 6 
 
Gibbs free energy change (∆G) HAT PCAF with quercetin  
Molecular docking between HAT PCAF and quercetin used AutoDock 
Vina which gives information about ∆G from binding mode between 
the ligand and its receptor. The best model was chosen based on ∆G 
value because it showed conformation stability between HAT PCAF 
and quercetin. HAT PCAF and quercetin reaction could be possible if 
∆G<0 that means complex formation reaction is spontaneous [19]. The 
∆G value of this molecular docking was-7.5 kcal/mol for HAT PCAF 
chain A, and-8.0 kcal for HAT PCAF chain B (fig. 1). This value was 
lower than ∆G of HAT PCAF and CoA, its natural ligand, but not that 
significant. This suggested that HAT PCAF–quercetin bond was more 
stable and more spontaneous compared to HAT PCAF–CoA.  
 
 
Fig. 1: ∆G of molecular docking between HAT PCAF with CoA and 
quercetin 
 
Molecular docking between HAT PCAF and quercetin 
The molecular docking study used HAT PCAF crystallography from a 
previous study [4]. CoA connected to HAT PCAF through some 
noncovalent interactions which include hydrogen bond, hydrophobic 
interactions, and van der Waals forces. The residues include Cys574, 
Valine 576 (Val576), Lysine 583 (Lys583), Glycine 584 (Gly584), 
Threonine 587 (Thr587) that interact through hydrogen bonding, 
while Gln525, Cys574, Alanine 575 (Ala575), Val576, Gln581, Gly586, 
Ala613, Tyrosine 616 (Tyr616), and Phenylalanine 617 (Phe617) 
interact through Van der Waals interactions. The other binding site 
was histone binding site to HAT PCAF. Glutamic acid 570 (Glu570) was 
a binding site for lysine of histone on HAT PCAF and stabilized by 
Asp610 [4]. Glu570 was surrounded by some hydrophobic residues, 
Suryani et al. 
Int J Pharm Pharm Sci, Vol 8, Issue 5, 211-215 
213 
such as Phe563, Phe568, Ile571, Val572, Leucine 606 (Leu606), 
Isoleucine 637 (Ile637), and Tyr640 that raised the pKa of the 
glutamate side chain and thus facilitated proton extraction from the 
lysine substrate [4].  
The reaction mechanism of histone acetylation by HAT PCAF was 
preceded by the ternary complex formation between HAT PCAF, 
acetyl-CoA, and histone. The ε-amino group of Lys14 directly attacks 
the carbonyl of acetyl-CoA, transferring the acetyl moiety to the 
histone as acceptor peptide. The release of the product in the order, 
acetylated is the first, follow by CoA [22]. Therefore, development of 
HAT PCAF inhibitors can be done based on the acetylation mechanism, 
that is inhibitor bound to CoA and histone binding site in order the 
both substrates cannot interact with HAT PCAF, thus acetylation 
histone cannot occur. The other molecules that could interact through 
noncovalent interactions with the substrates binding site on HAT PCAF 
could have a potential as HAT inhibitors.  
Molecular docking predicted binding mode between HAT PCAF amino 
acid residues and quercetin. Chain A of HAT PCAF interacted with 
quercetin through hydrogen bond that involved Gln525, Cys574, 
Tyr608, and Asp610 (fig. 2). This binding mode had similarities with 
CoA binding site on HAT PCAF, those were Cys574 and Gln525. 
Hydroxyl groups of quercetin formed hydrogen bonds with an amine 
group (-NH2) and thiol group (-SH) of Cys574 with the bond distances 
were 4.55 and 4.25 Å, respectively. Quercetin also formed a hydrogen 
bond with the hydroxyl group of Gln525 with bond distance is 4.60 Å. 
Bond distances between quercetin and Cys574 were relatively weak 
compared to CoA binds to Cys574, but quercetin interaction with 
Gln525 was stronger than CoA to Gln525 because quercetin interacted 
through hydrogen bond, meanwhile CoA interacted through van der, 
Waals. Quercetin interaction was also stabilized by the hydrophobic 
interaction that involved the same amino acid residues of CoA binding 
sites, which were Ala575, Ala613, Tyr616, and Phe617. This indicated 
that quercetin could have the potentiality to compete with CoA. 
Another hydrogen bond was formed between quercetin and Asp610 
which was an amino acid that was involved in the binding of histone at 
PCAF thus alleged that quercetin was also bound to the histone binding 
site, and this indicated that quercetin also could have competed with 
histone. This molecular docking predicted that quercetin could be the 
competitive inhibitor for both CoA and histone on chain A HAT PCAF. 
  
 
Fig. 2: Chain A HAT PCAF interaction with quercetin a) hydrogen bond; b) hydrophobic interaction. The red circle showed the amino acids 
involved in the CoA binding, meanwhile, the green circle showed the amino acids involved in the histone binding 
 
 
Fig. 3: Chain B HAT PCAF interaction with quercetin a) hydrogen bond; b) hydrophobic interaction. The red circle shows the amino acids 
involved in the CoA binding, meanwhile, the green circle shows the amino acids involved in the histone binding 
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The hydrogen bond between quercetin and CoA binding sites also 
occurred at chain B HAT PCAF through Cys574 and Gln581 (fig. 3). 
Hydroxyl group from quercetin bound with amide group (-NH2) and 
a thiol group (-SH) of Cys574 with bond distances were 4.44 and 
4.57 Å, respectively. Quercetin also interacted with CoA binding sites 
through hydrophobic interaction that involved Ala575, Ala613, 
Tyr616, and Phe617. Quercetin on chain B HAT PCAF also bound to 
histone binding site, Asp610, and that was stabilized by Val572. The 
molecular interaction that occurred between quercetin and chain B 
HAT PCAF indicated that quercetin could be the competitive 
inhibitor for both CoA and histone on chain B HAT PCAF, the same as 
it happened with chain A. The kinetic inhibition assay in this study 
would give more information. The in vitro assay for this study was 
carried out with HAT PCAF inhibition kinetic assay. The other HAT 
PCAF amino acids that interacted with quercetin are shown in 
table 2. 
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HAT inhibition kinetics 
Study of   inhibitor potency to inhibit its target enzyme is done by 
inhibition kinetics assay. This assay gives information about Ki and 
type of inhibition. The information can be used to understand the 
interaction between inhibitor and its target enzyme in drug 
development. Inhibition kinetics of HAT PCAF by quercetin showed 
that quercetin inhibited HAT PCAF based on fluorescence intensity. 
The product of HAT PCAF reaction decreased by increasing quercetin 
concentrations increased. The result of Dixon plot analysis showed 
that the inhibition type of HAT PCAF by quercetin was competitive 
inhibition (fig. 4), with Ki values of 9.575 µM. Inhibition Competitive 
inhibition indicated that quercetin could bind to CoA’s binding site that 
could inhibit HAT PCAF activity [6]. Ki value indicated quercetin 
affinity against HAT PCAF, the smaller the Ki value, the higher the 
quercetin affinity for HAT PCAF, and vice versa [6]. The Ki value can be 
used as a quantitative comparison between quercetin affinity with 
histone and other inhibitors [6]. Affinity comparative of quercetin and 
histone could be compared based on the Ki value of quercetin with the 
KM value of histone which indicated its affinity for HAT PCAF [6]. Based 
on the comparison, quercetin affinity was slightly higher than histone, 
so that it can compete with histone on HAT PCAF. The same result was 
shown by molecular docking of quercetin and showed by molecular 
docking of quercetin and HAT PCAF.  
 
 
Fig. 4: Dixon plot of product formation rate (1/v) as a function of 
inhibitory concentration [I] 
 
HAT inhibition assay used quercetin as inhibitor and histone as a 
substrate in various concentrations, while CoA as a substrate in fixed 
concentration. The results of HAT inhibition assay showed that 
quercetin could inhibit HAT activity. HAT activity inhibition in this 
study was observed from the CoA concentration which was a product 
of HAT enzymatic reaction. CoA concentration was equivalent to the 
formation of acetylated histones [10]. Therefore, the low concentration 
of CoA showed that quercetin could inhibit histone acetylation reaction 
that catalyzed by HAT PCAF.  
The results of HAT inhibition assay by Dixon plot provided information 
about the type of HAT PCAF inhibition by quercetin. Inhibition type 
was observed from the intersection of the two lines of linear inhibition 
(fig. 4). The intersection of the lines above the x-axis (inhibitor 
concentration) indicates that inhibition of this enzyme is a competitive 
inhibition [12]. Quercetin as competitive inhibitor bound to the histone 
active site and inhibited H3 as HAT PCAF’s substrate to its binding site. 
This was leading to inhibition of acetyl transfer acetyl from acetyl-CoA 
to histone; thereby inhibit the formation of acetylated histones. 
Another information that we could get from this kinetics study was the 
value of inhibition constant (Ki) which was the concentration of 
inhibitor that was required decreasing decreasing a half of maximum 
reaction rate. Hence, the lower the Ki value was, the lower  the 
inhibitor concentration required to inhibit enzyme activity, and vice 
versa. Ki values could also be used to predict the interaction between 
inhibitor and enzyme. Ki value that was lower than plasma 
concentration showed that the interaction could occur, whereas if Ki 
was higher than the plasma concentration, the interaction could not 
occur [12]. Ki values for quercetin against HAT PCAF were 9.575 µM.  
CONCLUSION 
This study described quercetin potency as HAT PCAF inhibitor with in 
silico and in vitro approach. Quercetin binding mode on HAT PCAF 
used molecular docking. Quercetin bound to CoA active site through 
Gln525 and Cys574 on chain A, and through Cys574 and Gln581 on 
chain B HAT PCAF. Quercetin also bound to histone active site Asp610, 
Ile571, and Val572. The most important part of quercetin in binding 
HAT PCAF is a hydroxyl group. The result of molecular docking showed 
that quercetin could compete with both CoA and histone. Quercetin 
interaction with HAT PCAF is slightly more stable than the interaction 
between CoA and HAT PCAF based on ∆G value. The same indication 
happened to kinetics inhibition (in vitro). Quercetin against HAT PCAF 
affinity (Ki = 9.575 µM) is hihger the affinity of histone on HAT PCAF 
(KM = 10 µM), but the affinity was not significantly different. Dixon plot 
analysis also showed that quercetin competed with histone to inhibit 
HAT PCAF activity.  
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